FY26-27 Adult Covid-19 Vaccines

Solicitation / RFP / RFQ

This solicitation is for the procurement of standard commercial adult COVID-19 vaccines. The Centers for Disease Control and Prevention (CDC) intends to award one or more Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts. The primary goal is to procure vaccines for the 2026-2027 season, with a secondary requirement to purchase vaccines for the 2025-2026 season. These vaccines will be used to support adult immunization programs for state and local health departments, as well as other authorized awardees.

• Supplies/Service: COVID-19 Adult Vaccines (age 19 years and older).

• Period of Performance (PoP): 06/01/2026 – 05/31/2027.

• Contract Type: Firm Fixed Price Line Item with an ID/IQ contract structure.

• Vaccine Requirements:

  • Minimum 12-month shelf life upon delivery.
  • Packaging must maintain FDA recommended temperatures during transit.
  • Electronic temperature monitoring device required with each shipment.
  • Vaccines must be manufactured under a current FDA establishment and product license.
  • Compliance with Current Good Manufacturing Practice Regulations (CGMPRs).

• Delivery: Within 15 working days after receipt of order to designated CDC centralized distribution locations (Olive Branch, MS and Clermont, KY) or specific CDC Occupational Health Clinic locations.

• Ordering System: Vaccines will be ordered via delivery orders in the Vaccine Tracking System (VTrckS).

• Drug Supply Chain Security Act (DSCSA): Shipments must be compliant with DSCSA requirements.

• Contract Type: Firm Fixed Price ID/IQ.

• Maximum Contract Value: $892,363,500.00.

• Contract Period of Performance: 12 months from the date of award.

• Offer Submission Deadline: March 17, 2026, 1:00 PM EST.

• Questions Deadline: March 10, 2026, 1:00 PM EST.

• Submission Method: Electronically via email to specified CDC contacts.

• Evaluation Factors: Technical Proposal (meeting specific vaccine requirements, shelf life, FDA licensure, commercial price list submission), Price Proposal (unit prices including FET), and Past Performance.

• Offerors must propose FDA-approved vaccines.

• Offerors must meet Federal Ceiling Price (FCP) provisions.

• Offerors must meet Federal Excise Tax Credit provisions.

• Offerors must have the ability to interface with VTrckS.

• Small business offerors may be required to submit a subcontracting plan.

• The solicitation references numerous FAR and HHSAR clauses, including those related to payment, delivery, inspection, and records management.

• An Authorized Distributor of Record (ADR) Agreement is required (Attachment D-1).

• Offerors must be able to interface with the CDC's Vaccine Tracking System (VTrckS).

Form / Attachment / Pricing Sheet

This document is an Authorized Distributor of Record (ADR) Agreement between a Manufacturer/Supplier and the Centers for Disease Control and Prevention (CDC). It designates the CDC as an ADR for specific pharmaceutical or vaccine products, in compliance with the Prescription Drug Marketing Act (PDMA) of 1988 and its implementing regulations (21 CFR Part 203).

• The agreement requires the Manufacturer/Supplier to identify whether the CDC is an ADR for their entire product line or for specific products listed on an attachment (D-2).
• Specific products must be identified by pharmaceutical/vaccine name, dosage form, strength, and NDC number.
• The agreement is valid from dual execution until terminated by either party with 90 days' written notice.
• It confers no rights beyond the ADR designation and is not a sales agreement.

Bidders should review this agreement to understand the established relationship between the manufacturer and the CDC regarding drug distribution. This may be relevant if the opportunity involves the procurement or distribution of pharmaceuticals or vaccines where the CDC's role as an ADR is a factor. The agreement outlines the compliance requirements under the PDMA.

Form / Attachment / Pricing Sheet

This document, titled "List of Products," serves as an attachment to the opportunity record. It outlines specific products required by the government.

• Item Number
• Product/Brand Name
• National Drug Code (NDC)

Bidders should use this list to identify the specific products, such as vaccines, that are part of the government's requirement. This information is crucial for accurately preparing product offerings and pricing within their proposals.

Solicitation / RFP / RFQ

This document is a solicitation for commercial items, identified by Solicitation Number 75D301-26-R-73405. The issuing agency is the Centers for Disease Control and Prevention (CDC), Office of Acquisition Services.

• The specific supplies/services are detailed in the "See Schedule" section, indicating that further details are provided elsewhere.

• The solicitation is being issued as an RFP (Request for Proposal).

• The solicitation issue date is March 4, 2026.

• The award/effective date is June 1, 2026.

• The offer due date is March 17, 2026, at 1:00 PM EDT.

• Payment will be made by the Center of Disease Control (CDC), Office of Financial Resources.

• Offerors are required to sign this document and return one copy to the issuing office.

• The solicitation incorporates by reference FAR 52.212-1, 52.212-4, and 52.212-5. These clauses, along with any addenda, are attached.

• Invoices should be submitted to the address shown in Block 18a unless otherwise indicated.

• This acquisition is marked as "Unrestricted."

• The NAICS code is 325412, with a size standard indicated.

• The document is 32 pages in total.

• Standard Form 1449 is used for this solicitation.